What is mild cognitive impairment, and how is it different from "early Alzheimer's"?

What MCI is

Mild cognitive impairment, almost always shortened to MCI, is a clinical category for people whose thinking, memory, or other cognitive abilities have measurably declined - beyond what is expected for normal ageing - but who are still able to manage day-to-day activities largely on their own. They notice the change. People close to them notice it. A clinician doing a structured assessment can see it. But the impairment is not yet severe enough to meet the threshold for dementia.

MCI is a diagnostic category, not a disease. People meet criteria for MCI for many different reasons. The most common cause in older adults is underlying Alzheimer's pathology, but other causes include cerebrovascular disease, Lewy body pathology, frontotemporal degeneration, depression, sleep apnoea, medication side effects, and several reversible conditions. A clinician makes the MCI diagnosis based on the level of impairment - not on what is causing it.

Some people with MCI go on to develop dementia within a few years. Some progress more slowly. Some remain stable for long periods. A few improve, particularly when the underlying cause is reversible. The trajectory depends on the underlying cause, which is what newer diagnostic tools - biomarkers, imaging, structured neuropsychological testing - try to clarify.

Why "early Alzheimer's disease" is a different term

Until relatively recently, MCI was described primarily in clinical and behavioural terms. The Alzheimer's connection was inferred - clinicians made an educated assessment of how likely it was that a patient's MCI was caused by Alzheimer's pathology, but the underlying biology could only be confirmed at autopsy.

That has changed. With amyloid PET, tau PET, and now plasma biomarkers, the underlying Alzheimer's pathology can be confirmed in living patients. That allows the field to make a more specific diagnosis: not just "MCI" but "MCI due to Alzheimer's disease" - the cognitive level, with the underlying cause specified.

In clinical-trial and contemporary treatment settings, the term you will hear is "early Alzheimer's disease." This is shorthand for the population that includes:

• MCI due to Alzheimer's disease - patients meeting MCI criteria, with biomarker confirmation that Alzheimer's pathology is the underlying cause.
• Mild dementia due to Alzheimer's disease - patients whose impairment has progressed past MCI into the mild-dementia range, but is still in an early enough stage that the disease has not taken over their daily independence.

Both groups are usually scored in a similar range on global staging - typically CDR-SB values of roughly 2 to 6 - and both groups were enrolled in the pivotal anti-amyloid trials. The FDA labels for the contemporary anti-amyloid antibodies are written for "early Alzheimer's disease" in this combined sense.

Why the distinction matters in practice

Three reasons.

Treatment eligibility. The contemporary disease-modifying treatments - covered in our explainer on anti-amyloid antibodies - are approved for early Alzheimer's disease, with biomarker confirmation. A patient with MCI but no biomarker confirmation is not in scope for those therapies, regardless of clinical impression. A patient with biomarker-confirmed Alzheimer's pathology but moderate or severe dementia is also outside the approved label, because the trial evidence is in the early window.

Risk stratification and counselling. A patient with MCI who has biomarker-positive Alzheimer's pathology has a much higher likelihood of progressing to dementia, on a faster timescale, than a patient with MCI from another cause. The conversation with the patient and family changes when the underlying cause is known.

Trial enrolment. Most contemporary disease-modifying trials in Alzheimer's enrol the early Alzheimer's population specifically, with biomarker confirmation as a screening requirement. Patients with MCI from non-Alzheimer's causes - or with Alzheimer's pathology that is too advanced - are screened out at the eligibility stage.

What the diagnosis can and cannot tell you

It can tell you:

• The level of cognitive impairment, in standardised terms.
• Whether the impairment is consistent with MCI or has progressed into the dementia range.
• When combined with biomarkers, the most likely underlying cause.

It cannot tell you:

• Exactly when, or whether, an individual patient will progress.
• Which specific cognitive symptoms a patient will develop next.
• The right answer to most of the personal questions families ask after the diagnosis - about driving, work, financial planning, advance care decisions. Those decisions depend on the patient's specific situation and benefit from ongoing conversation with a clinical team.

The terminology that is changing

The clinical-research framework underlying these terms has continued to evolve. The 2024 NIA-AA framework formalised the use of biomarkers as the basis for an Alzheimer's disease diagnosis in living patients, and the language used in clinical and trial settings has been moving toward biomarker-anchored definitions accordingly. The colloquial usage in everyday clinical practice still varies - some clinicians describe a patient as "having MCI" while waiting for biomarker results, then refine the framing once the biology is confirmed.

The takeaway for patients and families: if you hear several different terms during a workup - MCI, early Alzheimer's, mild dementia due to Alzheimer's - they are not necessarily contradictory. They are likely tracking different parts of the same picture: the level of impairment, the underlying biology, and the diagnostic stage.

Where this fits in the bigger picture

MCI and early Alzheimer's disease are the categories the contemporary diagnostic and treatment infrastructure is built around. The diagnostic pathway - covered in our snapshot of diagnostic pathways for 2026 - is increasingly designed to identify these patients earlier, confirm the underlying cause, and route them toward appropriate treatment when one is available. The access constraints that shape that pathway are covered in our Insight on why the anti-amyloid rollout is rate-limited by infrastructure, not science.

This page is a plain-language primer. It is not medical advice. Decisions about diagnostic evaluation and treatment belong with the patient and their clinical team.